{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:39:49Z","timestamp":1792795189387,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Toxicol"],"DOI":"10.1007\/s00204-026-04577-8","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:50:22Z","timestamp":1792792222000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["From TD50 to benchmark dose in nitrosamine risk assessment: evidence from N-Nitrosotrimetazidine carcinogenicity and TGR mutation data"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9595-5763","authenticated-orcid":false,"given":"M\u00e9lanie","family":"Leheup","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5643-9942","authenticated-orcid":false,"given":"George E.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2713-7982","authenticated-orcid":false,"given":"David","family":"Kirkland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Griffon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6439-6030","authenticated-orcid":false,"given":"Richard J.","family":"Weaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9502-1409","authenticated-orcid":false,"given":"Flavia","family":"Pasello dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5898-3677","authenticated-orcid":false,"given":"Sylvain","family":"Fouliard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6549-8936","authenticated-orcid":false,"given":"Stefan O.","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"key":"4577_CR1","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/978-1-4615-8966-2_9","volume-title":"Chemical mutagens: principles and methods for their detection volume 1","author":"BN Ames","year":"1971","unstructured":"Ames BN (1971) The detection of chemical mutagens with enteric bacteria. Chemical mutagens: principles and methods for their detection volume 1. Springer, Boston, MA, pp 267\u2013282"},{"key":"4577_CR2","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/0165-1161(75)90046-1","volume":"31","author":"BN Ames","year":"1975","unstructured":"Ames BN, McCann J, Yamasaki E (1975) Methods for detecting carcinogens and mutagens with the Salmonella\/mammalian-microsome mutagenicity test. Mutat Res 31:347\u2013364","journal-title":"Mutat Res"},{"key":"4577_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrgentox.2023.503685","volume":"891","author":"JP Bercu","year":"2023","unstructured":"Bercu JP et al (2023) Comparison of the transgenic rodent mutation assay, error corrected next generation duplex sequencing, and the alkaline comet assay to detect dose-related mutations following exposure to N-nitrosodiethylamine. Mutat Res Genet Toxicol Environ Mutagen 891:503685","journal-title":"Mutat Res Genet Toxicol Environ Mutagen"},{"issue":"6","key":"4577_CR4","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.2903\/j.efsa.2009.1150","volume":"7","author":"EFSA Scientific Committee","year":"2009","unstructured":"EFSA Scientific Committee (2009) Guidance of the Scientific Committee on use of the benchmark dose approach in risk assessment. EFSA J 7(6):1150. https:\/\/doi.org\/10.2903\/j.efsa.2009.1150","journal-title":"EFSA J"},{"key":"4577_CR5","unstructured":"EMA (2024a)\u00a0Questions and answers for marketing authorisation holders\/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726\/2004 referral on nitrosamine impurities in human medicinal products. EMA\/409815\/2020 Rev.23"},{"key":"4577_CR6","unstructured":"EMA (2024b)\u00a0Questions and answers for marketing authorisation holders\/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726\/2004 referral on nitrosamine impurities in human medicinal products. Enhanced Ames Test Conditions for N-nitrosamines. EMA\/1203337\/2024"},{"key":"4577_CR7","volume-title":"ICH guideline S2 (R1) on genotoxicity testing and data interpretation for pharmaceuticals intended for human use","author":"European Medicines Agency","year":"2012","unstructured":"EMA (2012) ICH guideline S2 (R1) on genotoxicity testing and data interpretation for pharmaceuticals intended for human use. European Medicines Agency, United Kingdom"},{"key":"4577_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1289\/ehp.84589","volume":"58","author":"LS Gold","year":"1984","unstructured":"Gold LS, Sawyer CB, Magaw R et al (1984) A carcinogenic potency database of the standardized results of animal bioassays. Environ Health Perspect 58:9\u2013319","journal-title":"Environ Health Perspect"},{"key":"4577_CR10","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/(SICI)1098-2280(2000)35:3<253::AID-EM11>3.0.CO;2-J","volume":"35","author":"JA Heddle","year":"2000","unstructured":"Heddle JA, Dean S, Nohmi T et al (2000) In vivo transgenic mutation assays. Environ Mol Mutagen 35:253\u2013259","journal-title":"Environ Mol Mutagen"},{"key":"4577_CR11","volume-title":"S1B: Note for Guidance on Carcinogenicity: Testing for Carcinogenicity of Pharmaceuticals (CPMP\/ICH\/299\/95)","author":"ICH","year":"1995","unstructured":"ICH (1995) S1B: Note for Guidance on Carcinogenicity: Testing for Carcinogenicity of Pharmaceuticals (CPMP\/ICH\/299\/95). International Council for Harmonisation, Geneva"},{"key":"4577_CR12","volume-title":"S2(R1): Guidance on genotoxicity testing and data interpretation for pharmaceuticals intended for human use","author":"ICH","year":"2011","unstructured":"ICH (2011) S2(R1): Guidance on genotoxicity testing and data interpretation for pharmaceuticals intended for human use. International Council for Harmonisation, Geneva"},{"key":"4577_CR13","volume-title":"M7(R1): Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk","author":"ICH","year":"2017","unstructured":"ICH (2017) M7(R1): Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk. International Council for Harmonisation, Geneva"},{"key":"4577_CR14","volume-title":"M7(R2): Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk","author":"ICH","year":"2023","unstructured":"ICH (2023) M7(R2): Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk. International Council for Harmonisation, Geneva"},{"key":"4577_CR15","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1002\/em.21870","volume":"55","author":"GE Johnson","year":"2014","unstructured":"Johnson GE et al (2014) Derivation of point of departure (PoD) estimates in genetic toxicology studies and their potential applications in risk assessment. Environ Mol Mutagen 55:609\u2013623. https:\/\/doi.org\/10.1002\/em.21870","journal-title":"Environ Mol Mutagen"},{"issue":"5","key":"4577_CR16","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/em.22446","volume":"62","author":"GE Johnson","year":"2021","unstructured":"Johnson GE et al (2021) Permitted daily exposure limits for noteworthy N-nitrosamines. Environ Mol Mutagen 62(5):293\u2013305. https:\/\/doi.org\/10.1002\/em.22446","journal-title":"Environ Mol Mutagen"},{"key":"4577_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2026.106051","volume":"167","author":"Jolly","year":"2026","unstructured":"Jolly et al (2026) Ames concordance with the in vivo transgenic rodent (TGR) gene mutation assay for NDSRIs and relative in vivo TGR potency with nitrosamines with robust dose-response carcinogenicity data. Regul Toxicol and Pharmacol 167:106051","journal-title":"Regul Toxicol and Pharmacol"},{"key":"4577_CR18","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.mrgentox.2019.01.007","volume":"839","author":"D Kirkland","year":"2019","unstructured":"Kirkland D et al (2019) A comparison of transgenic rodent mutation and in vivo comet assay responses for 91 chemicals. Mutat Res 839:21\u201335","journal-title":"Mutat Res"},{"key":"4577_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mrrev.2005.04.002","volume":"590","author":"IB Lambert","year":"2005","unstructured":"Lambert IB, Singer TM, Boucher SE, Douglas GR (2005) Detailed review of transgenic rodent mutation assays. Mutat Res 590:1\u2013280","journal-title":"Mutat Res"},{"key":"4577_CR20","doi-asserted-by":"crossref","unstructured":"Loeppky RN, Michejda CJ (1994)\u00a0Nitrosamines and related N-Nitroso compounds: chemistry and biochemistry. ACS Symposium Series, Vol. 553. American Chemical Society, Washington, DC.","DOI":"10.1021\/bk-1994-0553"},{"key":"4577_CR21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.mrgentox.2014.09.011","volume":"783","author":"JT MacGregor","year":"2015","unstructured":"MacGregor JT, Fr\u00f6tschl R, White PA et al (2015a) IWGT report on quantitative approaches to genotoxicity risk assessment I. Methods and metrics for defining exposure\u2013response relationships and points of departure (PoDs). Mutat Res Genet Toxicol Environ Mutagen 783:55\u201365. https:\/\/doi.org\/10.1016\/j.mrgentox.2014.09.011","journal-title":"Mutat Res Genet Toxicol Environ Mutagen"},{"key":"4577_CR22","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.mrgentox.2014.10.008","volume":"783","author":"JT MacGregor","year":"2015","unstructured":"MacGregor JT, Fr\u00f6tschl R, White PA et al (2015b) IWGT report on quantitative approaches to genotoxicity risk assessment II. Use of point-of-departure (PoD) metrics in defining acceptable exposure limits and assessing human risk. Mutat Res Genet Toxicol Environ Mutagen 783:66\u201378. https:\/\/doi.org\/10.1016\/j.mrgentox.2014.10.008","journal-title":"Mutat Res Genet Toxicol Environ Mutagen"},{"key":"4577_CR23","volume-title":"Test no. 471: bacterial reverse mutation test","author":"OECD","year":"1997","unstructured":"OECD (1997) Test no. 471: bacterial reverse mutation test. OECD Publishing, Paris"},{"key":"4577_CR24","doi-asserted-by":"publisher","DOI":"10.1787\/9789264264885-en","volume-title":"Test no. 489: in vivo mammalian alkaline comet assay","author":"OECD","year":"2016","unstructured":"OECD (2016a) Test no. 489: in vivo mammalian alkaline comet assay. OECD Publishing, Paris"},{"key":"4577_CR25","doi-asserted-by":"publisher","DOI":"10.1787\/9789264264762-en","volume-title":"Test no. 474: mammalian erythrocyte micronucleus test","author":"OECD","year":"2016","unstructured":"OECD (2016b) Test no. 474: mammalian erythrocyte micronucleus test. OECD Publishing, Paris"},{"key":"4577_CR26","doi-asserted-by":"publisher","DOI":"10.1787\/9789264071186-en","volume-title":"Test no. 451: carcinogenicity studies","author":"OECD","year":"2018","unstructured":"OECD (2018) Test no. 451: carcinogenicity studies. OECD Publishing, Paris"},{"key":"4577_CR27","doi-asserted-by":"publisher","DOI":"10.1787\/9789264203907-en","volume-title":"Test no. 488: transgenic rodent somatic and germ cell gene mutation assays","author":"OECD","year":"2025","unstructured":"OECD (2025) Test no. 488: transgenic rodent somatic and germ cell gene mutation assays. OECD Publishing, Paris"},{"key":"4577_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1289\/ehp.84581","volume":"58","author":"R Peto","year":"1984","unstructured":"Peto R et al (1984) The TD50: a proposed general convention for the numerical description of the carcinogenic potency of chemicals in chronic-exposure animal experiments. Environ Health Perspect 58:1\u20138. https:\/\/doi.org\/10.1289\/ehp.84581","journal-title":"Environ Health Perspect"},{"key":"4577_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2024.105762","volume":"156","author":"DJ Ponting","year":"2025","unstructured":"Ponting DJ et al (2025) Control of N-nitrosamine impurities in drug products: progressing the current CPCA framework and supporting the derivation of robust compound specific acceptable intakes. Regul Toxicol Pharmacol 156:105762","journal-title":"Regul Toxicol Pharmacol"},{"issue":"2","key":"4577_CR30","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/0027-5107(78)90259-2","volume":"57","author":"TK Rao","year":"1978","unstructured":"Rao TK, Young JA, Lijinsky W, Epler JL (1978) Mutagenicity of N-nitrosopiperazine derivatives in Salmonella typhimurium. Mutat Res 57(2):127\u2013134","journal-title":"Mutat Res"},{"issue":"1","key":"4577_CR31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2307\/2530741","volume":"40","author":"C Sawyer","year":"1984","unstructured":"Sawyer C, Peto R, Bernstein L, Pike MC (1984) Calculation of environmental carcinogens: the TD50. Biometrics 40(1):27\u201339","journal-title":"Biometrics"},{"issue":"3","key":"4577_CR32","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3109\/10408444.2013.853726","volume":"44","author":"W Slob","year":"2014","unstructured":"Slob W, Setzer RW (2014) Shape and steepness of toxicological dose-response relationships of continuous endpoints. Crit Rev Toxicol 44(3):270\u2013297","journal-title":"Crit Rev Toxicol"},{"key":"4577_CR33","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s00204-024-03951-8","volume":"99","author":"R Thomas","year":"2025","unstructured":"Thomas R et al (2025) Critical comparison of BMD and TD50 methods for the calculation of acceptable intakes for N-nitroso compounds. Arch Toxicol 99:983\u2013993","journal-title":"Arch Toxicol"},{"key":"4577_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2020.104749","volume":"116","author":"A Thresher","year":"2020","unstructured":"Thresher A, Thomas R, Ponting DJ (2020) Are all nitrosamines concerning? A review of mutagenicity and carcinogenicity data. Regul Toxicol Pharmacol 116:104749","journal-title":"Regul Toxicol Pharmacol"},{"key":"4577_CR35","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.mrgentox.2003.07.004","volume":"540","author":"V Thybaud","year":"2003","unstructured":"Thybaud V, Dean S, Nohmi T et al (2003) In vivo transgenic mutation assays. Mutat Res Genet Toxicol Environ Mutagen 540:141\u2013151","journal-title":"Mutat Res Genet Toxicol Environ Mutagen"},{"key":"4577_CR36","unstructured":"U.S. EPA (2012) Benchmark dose technical guidance. Risk Assessment Forum, Washington, DC, EPA\/100\/R-12\/001."},{"key":"4577_CR37","unstructured":"FDA Guidance for Industry (2001) Guidance for Industry: statistical aspects of the design, analysis, and interpretation of chronic rodent carcinogenicity studies of pharmaceuticals. FDA, Silver Spring"},{"key":"4577_CR38","unstructured":"FDA Guidance for Industry (2003) Providing regulatory submissions in electronic format - general considerations. FDA, Silver Spring"},{"issue":"3","key":"4577_CR39","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/em.22422","volume":"62","author":"RP Wheeldon","year":"2021","unstructured":"Wheeldon RP et al (2021) The use of benchmark dose uncertainty measurements for robust comparative potency analyses. Environ Mol Mutagen 62(3):203\u2013215","journal-title":"Environ Mol Mutagen"},{"key":"4577_CR40","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/em.70006","volume":"66","author":"PA White","year":"2025","unstructured":"White PA, Chen G, Chepelev N et al (2025) Benchmark response (BMR) values for in vivo mutagenicity endpoints. Environ Mol Mutagen 66:172\u2013184. https:\/\/doi.org\/10.1002\/em.70006","journal-title":"Environ Mol Mutagen"},{"issue":"12","key":"4577_CR41","doi-asserted-by":"publisher","first-page":"3799","DOI":"10.1007\/s00204-017-2037-3","volume":"91","author":"A Zeller","year":"2017","unstructured":"Zeller A et al (2017) An appraisal of critical effect sizes for the benchmark dose approach to assess dose-response relationships in genetic toxicology. Arch Toxicol 91(12):3799\u20133807. https:\/\/doi.org\/10.1007\/s00204-017-2037-3","journal-title":"Arch Toxicol"}],"container-title":["Archives of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-026-04577-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00204-026-04577-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-026-04577-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:50:25Z","timestamp":1792792225000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00204-026-04577-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":40,"alternative-id":["4577"],"URL":"https:\/\/doi.org\/10.1007\/s00204-026-04577-8","relation":{},"ISSN":["0340-5761","1432-0738"],"issn-type":[{"value":"0340-5761","type":"print"},{"value":"1432-0738","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"31 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. G.Johnson and D.Kirkland are expert consultants who have received funding from Servier and other pharmaceutical companies.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal studies were conducted in accordance with relevant national and international guidelines for the care and use of laboratory animals and were approved by the appropriate institutional ethics committees.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}